Pharma BD Deal Intelligence

Tolerance Bio, Inc. / NeoImmuneTech, Inc.

2026 · Licensing/Option · $260M · Complete

Tolerance Bio licensed efineptakin alfa (NT-I7), NeoImmuneTech's clinical-stage long-acting interleukin-7 fusion protein, for certain thymus-related indications in the Americas and Europe. Consideration comprises equity in Tolerance Bio, up to $260 million in development and sales milestones, and tiered royalties on net sales; no upfront cash payment was disclosed. Tolerance Bio plans Phase 2 trials testing the asset's ability to enhance thymic function, with HIV immunological non-response among the initial target indications.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals